VitiGam(TM) Inhibits Melanoma Growth in a Dose Dependent Manner

  
    
  
  
    
      GammaCan International, Inc. (“GammaCan” 
      or “the Company”) 
      (OTCBB: GCAN), a developer of proprietary immunotherapies for the 
      treatment of melanoma and other cancers, today announced further 
      progress in its VitiGam™ development 
      program. In preparation for its upcoming IND submission for VitiGam™, 
      the Company successfully completed additional experiments using its 
      established mouse melanoma model. These studies demonstrate a dose 
      response of tumors (human melanoma cells) when treated with IgG 
      preparations derived from vitiligo donors. In addition, the Company has 
      conducted a meta-analysis (a statistical analysis of a large number of 
      experiments) based on a series of previously announced studies with its 
      mouse melanoma model. The results of this meta-analysis further confirm 
      the effectiveness against melanomas of IgG preparations derived from 
      vitiligo donors.
    
    
      Using the A375 human melanoma cell line in SCID mice, the Company 
      demonstrated that vitiligo-derived IgG preparations can prevent the 
      growth of melanomas in a dose dependant manner. In these studies, mice 
      with subcutaneously induced melanomas were treated with varying 
      concentrations of vitiligo-derived IgG preparations and compared to 
      saline treated mice. At higher doses, vitiligo-derived IgG preparations 
      reduced tumor sizes by fifty percent and greater when compared to lower 
      doses.
    
    
      The Company also conducted a meta-analysis to further confirm the 
      overall effectiveness of vitiligo-derived IgG preparations against 
      melanoma cells. This analysis revealed a specific and highly 
      statistically significant inhibition of tumor growth in mice treated 
      with vitiligo-derived IgG preparations. Specifically, the Company 
      observed that two separate pools of vitiligo-derived IgG preparations 
      were able to inhibit tumor growth in a highly statistically significant 
      manner (p=0.006) compared to control mice receiving saline. In addition, 
      this analysis substantiated that anti-melanoma effects are specific to 
      vitiligo-derived IgG preparations. Tumors in mice treated with 
      vitiligo-derived preparations were significantly smaller (p=0.043) when 
      compared to tumors in mice treated with IgG preparations from 
      non-vitiligo donors.
    
    
      Steven Katz, Chairman of the Board and President of GammaCan said, “These 
      analyses confirm the validity of our anti-melanoma program. Using our 
      models, we have repeatedly demonstrated that vitiligo-derived IgG 
      preparations can prevent tumor growth. Further, we have observed a dose 
      response to vitiligo-derived IgG-based therapy.” 
      Mr. Katz further commented that, “These 
      positive results continue to keep us on track to file our IND with the 
      U.S. Food and Drug Administration in the near term.”
    
    
      About GammaCan
    
    
      GammaCan develops proprietary immunotherapy and related approaches to 
      treat melanoma and other cancers. GammaCan's patented platform 
      technology is based on the use of IgGs (gamma-immunoglobulins), a safe, 
      relatively non-toxic human plasma-derived product used to treat a 
      variety of immune deficiencies and autoimmune diseases. In cancer, 
      IgG-based therapies work by strengthening the patient's immune system. 
      Many experts currently view immunotherapy as a future alternative to 
      chemotherapy. The Company's lead drug candidate, VitiGam™, 
      targets Stage III and Stage IV melanoma for which no effective treatment 
      currently exists. In August 2007, VitiGam™ 
      received Orphan Drug designation from the U.S. Food and Drug 
      Administration (FDA) for the treatment of Stage IIB to Stage IV 
      metastatic melanoma. For more information about GammaCan, visit www.GammaCan.com.
    
    
      About VitiGam™
    
    
      VitiGam™ is a first-in-class IgG-based 
      anti-cancer immunotherapy being developed for the treatment of Stage III 
      and Stage IV melanoma. GammaCan is planning to submit its 
      Investigational New Drug Application (IND) for VitiGam™ 
      to the FDA in the near future. The Company expects to commence human 
      clinical trials shortly thereafter. VitiGam™ 
      is an IgG-based product manufactured from the plasma of donors with 
      Vitiligo, a benign skin condition affecting up to 2% of the general 
      population. Studies have shown that this "enriched" IgG formulation 
      contains potent anti-melanoma activity. Based on these studies, GammaCan 
      expects VitiGam™ to provide specific 
      anti-melanoma activity against melanoma cells, as well as non-specific 
      anti-cancer activity.
    
    
      About Melanoma
    
    
      Melanoma is a deadly form of skin cancer. According to the American 
      Cancer Society, melanoma accounts for approximately 4% of all skin 
      cancers but causes approximately 75% of all skin cancer-related deaths. 
      An estimated 62,500 people will be diagnosed with metastatic melanoma 
      (Stage III and Stage IV) in 2008; the prognosis is poor since no 
      effective treatment currently exists. These patients have a median 
      survival time of 8.5 months and a 5-year survival rate of less than 10%. 
      There has been little change in these results for in excess of 25 years. 
      The incidence of melanoma has increased more rapidly than any other 
      cancer during the past 10 years. The last drug to treat patients with 
      metastatic melanoma was approved by the FDA over 30 years ago.
    
    
      Safe Harbor Statement
    
    
      Statements in this press release that are not purely historical are 
      forward-looking statements. Forward-looking statements in this press 
      release include statements regarding: the commercialization of 
      anti-cancer immunotherapies and the Company's efforts to develop 
      therapies to boost the immune systems of cancer patients by the use of 
      IgG-based therapy. Actual outcomes and the Company's actual results 
      could differ materially from those in such forward-looking statements. 
      Factors that could cause actual results to differ materially include 
      risks and uncertainties such as the inability to finance the planned 
      development of the technology; the inability to hire appropriate staff 
      to develop the technology; unforeseen technical difficulties in 
      developing the technology; the inability to obtain regulatory approval 
      for human use; competitors' therapies proving to be more effective, 
      cheaper or otherwise preferable for consumers; the inability to market a 
      product; all of which could, among other things, delay or prevent 
      product release, as well as other factors expressed from time to time in 
      GammaCan's periodic filings with the Securities and Exchange Commission 
      (the "SEC"). As a result, this press release should be read in 
      conjunction with GammaCan's periodic filings with the SEC, which are 
      incorporated herein by reference. The forward-looking statements 
      contained herein are made only as of the date of this press release and 
      GammaCan undertakes no obligation to publicly update such 
      forward-looking statements to reflect subsequent events or circumstances.